Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth

Core Viewpoint - The market anticipates Harrow (HROW) will report a year-over-year increase in earnings driven by higher revenues when it releases its results for the quarter ended December 2025 [1] Earnings Expectations - Harrow is expected to post quarterly earnings of $0.40 per share, reflecting a year-over-year increase of +60% [3] - Revenues are projected to reach $88.8 million, which is an increase of 32.9% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 1.45% higher in the last 30 days, indicating a reassessment by analysts [4] - However, the Most Accurate Estimate for Harrow is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.42% [12] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with positive readings being more predictive of earnings beats [9][10] - Harrow's current Zacks Rank is 4, which complicates the prediction of an earnings beat [12] Historical Performance - In the last reported quarter, Harrow exceeded the expected earnings of $0.22 per share by delivering $0.33, resulting in a surprise of +50% [13] - Over the past four quarters, Harrow has beaten consensus EPS estimates two times [14] Industry Comparison - BioCryst Pharmaceuticals (BCRX), another player in the Zacks Medical - Drugs industry, is expected to report earnings of $0.07 per share, indicating a year-over-year change of +153.9% [18] - BioCryst's revenues are expected to be $149.38 million, up 13.6% from the previous year, with a higher Most Accurate Estimate leading to an Earnings ESP of +23.08% [19]